Clinical Trials World Congress

 

Discover. Develop. Get to market.

15-17 October | Congress Centre Basel

 

 
1,500+
Attendees
600+
1-2-1 Meetings
350+
Speakers
90+
Exhibitors
4
Co-located events

 

CLINICAL AGENDA AT A GLANCE

 

 

Day 1 – Tuesday 15th October 2019
Keynotes: Operationalising Clinical Trials
Chair’s opening remarks Andy Lee, Head of Global Clinical Trial Operations, MSD (CONFIRMED)
Networking Break
Roundtable discussion session
Networking Lunch
Track 1 Precision and Molecular Profiling Identifying Biomarkers Track 2 Partnering with Sponsors, Sites and CROs
Afternoon refreshments
Complex Clinical Trial Designs
Chair: Andy Lee, Head of Global Clinical Trial Operations, MSD
Chair’s end of day 1 remarks
Offsite Networking Drinks

 

 

Day 2 – Wednesday 16th October 2019
Innovation in Clinical Trials – Disruptive Technologies
The future of clinical trials – how to make it work?
Panel discussion: what’s slowing down uptake of technology in clinical trials?
Networking Break
Track 1 Data and Analytics Track 2 Innovation in Clinical Trials
Networking Lunch
Patient Recruitment and Retention
Afternoon refreshments
WORKSHOP: Cross-industry collaboration evaluating how Blockchain can transform the pharmaceutical and healthcare industry, part of emerging trends & technology PhUSE workgroup
Patient Engagement
Chair: Miroslava Prades-Ogorelkova, Clinical Trials Manager, ISDIN, Independent Expert – Evaluator, European Commission
Enabling patient centricity and remote trials in clinical development through at home sample collection
● Traditional approaches for measurement of drug exposure in clinical trials involves having the patient travel to a clinical site for collection of venous blood
● This puts a burden on the patient while also limiting the opportunities for assessment of drug exposure or other measurements to these clinical visits.
● The ability to collect samples at home would provide a more patient centric approach, enabling remote trials
● At home collection would provide benefit for
1) disease areas associated with episodic events (e.g. asthma, migraine, etc.),
2) long half-life compounds,
3) assessment of adherence,
4) developing understanding of adherence patterns for new dosing regimens (i.e. QWeekly, QMonthly), and
5) more frequent assessment of biomarkers of efficacy and toxicity
● This talk will share results from recent clinical pilot studies employing at home sampling technologies
Kevin Bateman, Scientific Associate Vice President, Merck (CONFIRMED)
Reserved for sponsor
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Patient engagement with paediatric patients, is not real fiction
● Involving children in drug development
● Who, When, What and Why
● Return on investment
● Young Persons Advisory Groups and parents
● Good practices
Begoña Nafría Escalera, Patient Engagement Lead, Hospital Sant Joan de Déu (CONFIRMED)
Collecting patient experience data to inform decision-making in R&D
Mareile Hark, Director of Strategy and Operations, Novartis (CONFIRMED)
Shared decision making and patient satisfaction
● How is patient involvement in the treatment decision related to patient satisfaction?
● What is the role of biologics in achieving patient satisfaction?
● Do patients from different cultures have different views on patient involvement?
Jörg Mahlich, Head of Health Economics and Outcomes Research, Janssen (CONFIRMED)
Chair’s closing remarks
On site drinks reception

 

 

Day 3 – Thursday 17th October 2019
Data Sharing and Industry Collaboration
Case Study: working with collaborators in combination studies – CIT and beyond
Panel Discussion: the value of sharing clinical trial data and challenges
Networking Break
Real World Evidence
Networking Lunch
Early Clinical Development
Chair’s closing remarks
End of conference – see you in 2020!

 

SESSIONS YOU CAN'T MISS

 

Case Study: working with collaborators in combination studies – CIT and beyond

• Looking at combination studies – CIT and beyond
• Working with collaborators in order to optimize performance
• Highlighting the key factors in making all collaborations successful

Denise Steckel , Head, Clinical Collaborations Management , Genentech

Increasing complexity of study design: the double-edged sword

• Patient recruitment challenges in complex clinical trials
• Considerations and approaches to shield patients from complexity

Chris Macdonald , Head Of Research , Pancreatic Cancer U.K.

Kefeng (Kevin) Hua | Senior Manager Al Data Mining Dev | Bayer » speaking at Festival of Biologics

Risk-adjusted planning for clinical trial process Optimization

• Clinical trials are expensive and risky business expenditures
• Accurate planning of clinical trials is difficult given the number and variety of uncertainties and the undeterministic nature of the trials
• Mining data from historical clinical trials to identify the risk factors and their impact on the variances of durations and costs can be used to define risk-adjusted planning for future trials
• Actionable measures can also be identified and simulated on reduction of time and costs for more efficient planning and execution of clinical trials

Kefeng (Kevin) Hua , Senior Manager Al Data Mining Dev , Bayer

The future of clinical trials – how to make it work?

• Exemplifying of how an agile approach is being used in pharma to support digital transformation
• Analysing this customer-centric approach, which can have real impact on the way we address clinical research
• Presenting concrete examples on how we apply design thinking to (digital) innovation in pharma
• How to set yourself up for innovation

Alain Bindels , Head Of Innovation Facilitation , Roche

Enabling patient centricity and remote trials in clinical development through at home sample collection

• Traditional approaches for measurement of drug exposure in clinical trials involves having the patient travel to a clinical site for collection of venous blood
• This puts a burden on the patient while also limiting the opportunities for assessment of drug exposure or other measurements to these clinical visits.
• The ability to collect samples at home would provide a more patient centric approach, enabling remote trials
• The benefits of at home collection

Kevin Bateman , Scientific Associate Vice President , MSD

Benefit-risk evaluation of immunotherapies today: a discussion of EMA/FDA Guidance for Industry

• Modernizing the reporting, collection, assessment of adverse events
• Patient reporting outcome
• Benefit-risk balance evaluation

Celine Adessi , Safety Science Senior Group Director Pred Oncology , Roche

speaking at Festival of Biologics

Panel Discussion: the value and challenges of sharing clinical trial data

Moderator: Olivier Leconte, Head of Statistical Programming & Analysis, Johnson & Johnson
 
Christian Ohmann, Chair of the Network Committee, European Clinical Research Infrastructure Network
Alun Bedding, Director Biostatistics, Roche Benjamin Szilagyi, Global Head Medical Data & Information Solutions, Roche
Sybille Eibert, Associate Director Transparency and Disclosure, Teva

 

 

Sign Up for Event Updates

 

 

There are two parts to the Festival of Biologics: four conferences covering Antibodies, Immunotherapy, Biosimilars and Clinical Trials and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.